A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer ; volume:134 ; number:1 ; day:24 ; month:12 ; year:2011 ; pages:13-20 ; date:7.2012
Breast cancer research and treatment ; 134, Heft 1 (24.12.2011), 13-20, 7.2012
- Creator
-
Rugo, Hope S.
Jo Chien, A.
Franco, Sandra X.
Stopeck, Alison T.
Glencer, Alexa
Lahiri, Soumi
Arbushites, Michael C.
Scott, Janet
Park, John W.
Hudis, Clifford
Nulsen, Ben
Dickler, Maura N.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-011-1918-z
- URN
-
urn:nbn:de:101:1-2019073121215923762244
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rugo, Hope S.
- Jo Chien, A.
- Franco, Sandra X.
- Stopeck, Alison T.
- Glencer, Alexa
- Lahiri, Soumi
- Arbushites, Michael C.
- Scott, Janet
- Park, John W.
- Hudis, Clifford
- Nulsen, Ben
- Dickler, Maura N.
- SpringerLink (Online service)
Other Objects (12)
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Gab2 Ablation Reverses the Stemness of HER2-Overexpressing Breast Cancer Cells
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis
Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines